Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Direct intratumoral injection of SD-101 with local radiation is safe in patients with relapsed or refractory lymphoma after allogeneic hematopoietic cell transplant.

Principal Investigator

Stanford Investigator(s)

CONTACT INFORMATION

Primary Contact:
Physician Referrals
(650) 723-0822